October 8, 2024
Authored and Edited by Daniel F. Klodowski; Umber Aggarwal; A. Sasha Hoyt; Deena Kablaoui Lanier; Elliot C. Cook
In July, a relatively difficult month for patent owners, the PTAB cancelled 582 (89.40%) instituted claims across 20 IPR and PGR Final Written Decisions, including decisions issued following remand from the Federal Circuit. After review, 63 (9.68%) instituted claims survived, and patent owners conceded 6 (0.92%) instituted claims through motions to amend or disclaimer. For comparison, the cumulative average cancellation rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 73%.

On a per-case basis, no instituted or substitute claims survived in 39 (81.25%) decisions, all instituted claims survived in 3 (6.25%) decision, and a mixed outcome occurred in 6 (12.5%) decisions. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision.

In August, a relatively favorable month for patent owners, the PTAB cancelled 261 (67.44%) instituted claims across 23 IPR and PGR Final Written Decisions. In those decisions, 126 (32.56%) instituted claims survived, and patent owners did not concede any instituted claims through motions to amend or disclaimer.

On a per-case basis, no instituted or substitute claims survived in 12 (52.17%) decisions, all instituted claims survived in 7 (30.43%) decisions, and a mixed outcome occurred in 4 (17.39%) decisions in August.

Through August 31, 2024, the PTAB has cumulatively granted 662 (15.90%) proposed substitute claims in motions to amend in IPRs, while denying 3,501 (84.10%) proposed substitute claims.

The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through August 31, 2024, broken down by technology center, is as follows:

The cumulative number of Final Written Decisions through August 31, 2024, separated by technology center, is as follows:

Additional cumulative statistics on the Board’s IPR, CBM, and PGR decisions, updated through August 31, 2024, are available here on the At the PTAB blog.
Copyright © 2024 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.